The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co’s immunotherapy drug combination to treat a form of skin cancer, setting the tone for other companies developing similar cocktails. This is the first time the FDA has approved a combination of two immuno-oncology drugs, Bristol-Myers said on Thursday, adding that the treatment will be available […]

Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology     September 24, 2015 05:00 PM Eastern Daylight Time   DARMSTADT, Germany & NEW YORK–(BUSINESS WIRE)–As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the […]

An early-stage study shows Bristol-Myers Squibb Co’s Opdivo treatment can be safely and effectively paired with relatively low and infrequent dosages of the company’s other immunotherapy, Yervoy, for patients with previously untreated lung cancer, researchers said on Monday. Opdivo, whose chemical name is nivolumab, is approved to treat advanced melanoma and the less-common squamous type […]

Giving cheap aspirin to cancer patients may turbo-charge the effectiveness of expensive new medicines that help their immune systems fight tumors, experiments on mice suggest. Immunotherapy promises to revolutionize cancer care by offering a better, longer-lasting response with fewer adverse side effects than conventional treatment, but the new drugs do not work well in all […]

Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments   WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the […]

NEW YORK–(BUSINESS WIRE)–Despite a slight drop in the number of FDA drug approvals during first half 2015 (1H15), treatments for cancer remain an important component of pharmaceutical companies’ R&D pipelines, according to a new Fitch Ratings report. One-third of all drugs approved by the FDA this year were cancer treatments, and positive early data on […]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung […]

Genentech (RHHBY)’s investigational cancer drug atezolizumab successfully shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1, the company announced this morning. Atezolizumab, MPDL3280A, is an investigational monoclonal antibody designed to interfere with a protein called PD-L1 (Programmed Death Ligand-1). Atezolizumab is designed to target PD-L1 expressed […]

Genentech (RHHBY) has partnered with several pharmaceutical companies, including AbbVie (ABBV), Clovis Oncology (CLVS) and Immune Design Corp. (IMDZ), as it ramps up its oncology pipeline. On Wednesday, Genentech and its partner AbbVie announced its promising experimental leukemia drug Venetoclax yielded a positive result in reducing the number of cancer cells in patients with previously […]

August 13, 2015By Mark Terry, Breaking News Staff Bristol-Myers Squibb Company (BMY) announced yesterday that after delivering additional clinical trial data regarding expanded use of cancer drug Opdivo, the U.S. Food and Drug Administration (FDA) had delayed the decision date in order to evaluate the new data. Originally the supplemental Biologics License Application (sBLA) […]